Which factors affect the choice of the inhaler in chronic obstructive respiratory diseases?

Pulmonary Pharmacology and Therapeutics

Volumn 31, Issue , 2015, Pages 63-67

  Scichilone, Nicola ^a   Benfante, Alida ^a   Bocchino, Marialuisa ^b   Braido, Fulvio ^c   Paggiaro, Pierluigi ^d   Papi, Alberto ^e   Santus, Pierachille ^f   Sanduzzi, Alessandro ^b  

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d UNIVERSITY HOSPITAL OF PISA   (Italy)

^e UNIVERSITY OF FERRARA   (Italy)

^f UNIVERSITY OF MILAN   (Italy)

Author keywords

Adherence; Asthma; COPD; Inhaler

Indexed keywords

CHRONIC OBSTRUCTIVE LUNG DISEASE; DRY POWDER INHALER; HUMAN; METERED DOSE INHALER; PARTICLE SIZE; PATIENT COMPLIANCE; PRESSURISED METERED DOSE INHALER; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; CHEMISTRY; INHALATIONAL DRUG ADMINISTRATION; MEDICATION COMPLIANCE; NEBULIZER; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SOLUTION AND SOLUBILITY; SUSPENSION;

ANTIASTHMATIC AGENT; SOLUTION AND SOLUBILITY; SUSPENSION;

ADMINISTRATION, INHALATION; ANTI-ASTHMATIC AGENTS; DRY POWDER INHALERS; HUMANS; MEDICATION ADHERENCE; METERED DOSE INHALERS; NEBULIZERS AND VAPORIZERS; PARTICLE SIZE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SOLUTIONS; SUSPENSIONS;

EID: 84926370957     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2015.02.006     Document Type: Review

References (30)

1. Laube B.L., Janssens H.M., de Jongh F.H., Devadason S.G., Dhand R., Diot P., et al. What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J 2011, 37(6):1308-1331.
2. Dolovich M.B., Ahrens R.C., Hess D.R., Anderson P., Dhand R., Rau J.L., et al. Device selection and outcomes of aerosol therapy: evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest 2005, 127(1):335-371.
3. Rubin B.K. Pediatric aerosol therapy: new devices and new drugs. Respir Care 2011 Sep, 56(9):1411-1421.
4. Giraud V., Roche N. Misuse of corticosteroid metered-dose inhaler is associated with decreased asthma stability. Eur Respir J 2002, 19(2):246-251.
5. van der Palen J., Klein J.J., van Herwaarden C.L., Zielhuis G.A., Seydel E.R. Multiple inhalers confuse asthma patients. Eur Respir J 1999, 14(5):1034-1037.
6. Dalby R.N., Eicher J., Zierenberg B. Development of respimat soft mist inhaler and its clinical utility in respiratory disorders. Med Devices Auckl 2011, 4:145-155.
7. Tarsin W.Y., Pearson S.B., Assi K.H., Chrystyn H. Emitted dose estimates from Seretide Diskus and Symbicort Turbuhaler following inhalation by severe asthmatics. Int J Pharm 2006, 316(1-2):131-137.
8. Chrystyn H. Anatomy and physiology in delivery: can we define our targets?. Alergy 1999, 54(Suppl.49):82-87.
9. Fabbri L.M., Nicolini G., Olivieri D., Papi A. Inhaled beclometasone dipropionate/formoterol extra-fine fixed combination in the treatment of asthma: evidence and future perspectives. Expert Opin Pharmacother 2008, 9(3):479-490.
10. Hozawa S., Terada M., Hozawa M. Comparison of budesonide/formoterol Turbuhaler with fluticasone/salmeterol Diskus for treatment effects on small airway impairment and airway inflammation in patients with asthma. Pulm Pharmacol Ther 2011, 24(5):571-576.
11. Leach C.L., Kuehl P.J., Chand R., Ketai L., Norenberg J.P., McDonald J.D. Characterization of respiratory deposition of fluticasone-salmeterol hydrofluoroalkane-134a and hydrofluoroalkane-134a beclomethasone in asthmatic patients. Ann Allergy Asthma Immunol 2012, 108(3):195-200.
12. Olsson B. Aerosol particle generation from dry powder inhalers: can they equal pressurized metered dose inhalers?. JAerosol Med 1995, 8(Suppl.3):S13-S18.
13. Zanen P., Go L.T., Lammers J.W. Optimal particle size for β2-agonists and anticholinergic aerosols in patients with severe airflow obstruction. Thorax 1996, 51:977-980.
14. Usmani O., Biddiscombe M.F., Nightingale J.A., Underwood S.R., Barnes P.J. Effects of bronchodilator particle size in asthmatic patients using monodisperse aerosols. JAppl Physiol 2003, 95:2106-2112.
15. Thorsson L., Edsbäcker S., Källén A., Löfdahl C.G. Pharmacokinetics and systemic activity of fluticasone via Diskus and pMDI, and of budesonide via Turbuhaler. Br J Clin Pharmacol 2001, 52(5):529-538.
16. Thorsson L., Kenyon C.J., Newman S.P., Borgström L. Lung deposition of budesonide in asthmatics: a comparison of different formulations. Int J Pharm 1998, 168(1):119-127.
17. Borgström L., Asking L., Thorsson L. Idealhalers or realhalers? A comparison of Diskus and Turbuhaler. Int J Clin Pract 2005 Dec, 59(12):1488-1495.
18. Agertoft L., Pedersen S. Lung deposition and systemic availability of fluticasone Diskus and budesonide Turbuhaler in children. Am J Respir Crit Care Med 2003, 168(7):779-782.
19. Corradi M., Chrystyn H., Cosio B.G., Pirozynski M., Loukides S., Louis R., et al. NEXThaler, an innovative dry powder inhaler delivering an extrafine fixed combination of beclometasone and formoterol to treat large and small airways in asthma. Expert Opin Drug Deliv 2014 Sep, 11(9):1497-1506.
20. Colthorpe P., Voshaar T., Kieckbusch T., Cuoghi E., Jauernig J. Delivery characteristics of a low-resistance dry-powder inhaler used to deliver the long-acting muscarinic antagonist glycopyrronium. JDrug Assess 2013, 2:11-16.
21. Pavkov R., Mueller S., Fiebich K., Singh D., Stowasser F., Pignatelli G., et al. Characteristics of a capsule based dry powder inhaler for the delivery of indacaterol. Curr Med Res Opin 2010 Nov, 26(11):2527-2533.
22. ® device for the treatment of COPD: pharmacological and clinical profile 2013, vol. 5:503-517.
23. Dewar M.H., Jamieson A., McLean A., Crompton G.K. Peak inspiratory flow through Turbuhaler in chronic obstructive airways disease. Respir Med 1999 May, 93(5):342-344.
24. Borgstrom L., Derom E., Stahl E., Wahlin-Boll E., Pauwels R. The inhalation device influences lung deposition and bronchodilating effect of terbutaline. Am J Respir Crit Care Med 1996, 153:1636-1640.
25. Osterberg L., Blaschke T. Adherence to medication. NEngl J Med 2005 Aug 4, 353(5):487-497.
26. Graves M.M., Adams C.D., Portnoy J.M. Adherence in young children with asthma. Curr Opin Allergy Clin Immunol 2006, 6(2):124-127.
27. Bender B.G., Bender S.E. Patient-identified barriers to asthma treatment adherence: responses to interviews, focus groups, and questionnaires. Immunol Allergy Clin N Am 2005, 25(1):107-130.
28. Thomas M., Price D., Chrystyn H., Lloyd A., Williams A.E., von Ziegenweidt J. Inhaled corticosteroids for asthma: impact of practice level device switching on asthma control. BMC Pulm Med 2009, 9:1.
29. Hanania N.A., Wittman R., Kesten S., Chapman K.R. Medical personnel's knowledge of and ability to use inhaling devices. Metered-dose inhalers, spacing chambers, and breath-actuated dry powder inhalers. Chest 1994, 105(1):111-116.
30. Hess D.R. Aerosol delivery devices in the treatment of asthma. Respir Care 2008, 53(6):699-723.